Pivot Bio stock
Private-market facts for current and former Pivot Bio employees researching their stock.
Overview
Pivot Bio develops microbial crop nutrition products that fix atmospheric nitrogen directly on plant roots, reducing the need for synthetic fertilizer.
Selling Pivot Bio shares
Why shareholders consider selling
Shareholders in Pivot Bio may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Pivot Bio does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Pivot Bio stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Food & Agriculture sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Pivot Bio shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Pivot Bio shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Food & Agriculture market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round and its reported $2B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Pivot Bio shareholders
Exploring equity in Pivot Bio often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Pivot Bio most recently raised a Series D round . The company was valued at $2B. Total funding raised to date is approximately $617M.
Lead investors in this round include DCVC and Breakthrough Energy Ventures.
Founders & company background
Pivot Bio was founded in 2011 by Karsten Temme, Alvin Tamsir and is headquartered in Berkeley, CA.
Investors
Industry
Similar private companies
Latest Pivot Bio news
:max_bytes(150000):strip_icc()/Scouting-R5A_1744-028_corn-668d051673214993bb7b17ecab5efc2c.jpg)
Frequently asked questions
- Is Pivot Bio still a private company?
- Yes, Pivot Bio is currently a private company.
- What is Pivot Bio's latest funding round?
- Pivot Bio's most recent known round is Series D.
- What is Pivot Bio's valuation?
- Pivot Bio's latest reported valuation is $2B.
- Who are the investors in Pivot Bio?
- Notable investors include DCVC, Breakthrough Energy Ventures, Prelude Ventures, Temasek.
- Can I sell my Pivot Bio stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Pivot Bio stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Pivot Bio data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.